Epperly Melissa B, 4

What Happened

• Melissa B. Epperly, a director of Roivant Sciences Ltd. (ROIV), exercised 17,750 vested stock options and immediately sold all 17,750 resulting common shares on June 29, 2026.
• Exercise cost: 17,750 shares × $4.46 = $79,165. Gross sale proceeds: 15,002 shares × $34.32 = $514,869 and 2,748 shares × $34.71 = $95,383, for total gross proceeds ≈ $610,252. Net proceeds after exercise cost ≈ $531,087.
• This was an exercise-plus-sale (cashless-style) transaction — proceeds realized by selling the shares created from exercising options.

Key Details

• Transaction date: 2026-06-29; Form 4 filed 2026-07-01 (no late filing indicated in the provided data).
• Exercise price: $4.46 per share; shares acquired on exercise: 17,750.
• Sales: 15,002 shares at a weighted avg $34.32 (sales ranged $33.65–$34.64 per F1) and 2,748 shares at weighted avg $34.71 (sales ranged $34.65–$34.80 per F2).
• Footnote F3 indicates the options exercised were fully vested.
• Shares owned after the transaction: not disclosed in the provided excerpt.
• Transaction codes: M = option exercise/conversion; S = open-market sale.

Context

• This is a routine insider monetization: exercising vested options and selling the resulting shares. Because the shares were sold immediately, the transaction primarily converts option value to cash rather than signalling a buy decision.
• No indication here of a 10b5‑1 plan, gift, or other special arrangement in the provided notes; detailed per-price breakdowns are available from the filer on request per the footnotes.